Each module will include a moderated slide presentation reviewing key publications, presentations and ongoing trials in addition to a clinical decision-making track facilitated through the use of networked tablet technology.

MODULE 1: Hodgkin and Non-Hodgkin Lymphomas | 8:00 AM – 9:15 AM

• Selection of up-front treatment for chronic lymphocytic leukemia in younger and older patients with normal- and high-risk cytogenetics: FCR versus bendamustine/rituximab; roles of ibrutinib, idelalisib and obinutuzumab
• Efficacy of venetoclax; prevention of tumor lysis syndrome
• Optimal sequencing of ibrutinib, bortezomib and lenalidomide for relapsed/refractory (R/R) mantle-cell lymphoma
• Role of obinutuzumab/bendamustine and idelalisib in R/R follicular lymphoma
• Similarities and differences between approved and developmental PI3 kinase inhibitors (eg, copanlisib, duvelisib) and potential clinical implications
• Application of AETHERA trial results to clinical practice; patient selection for brentuximab vedotin (BV) consolidation after autologous stem cell transplant
• Incidence, recognition and management of BV side effects and toxicities
• Anti-PD-1/PD-L1 antibodies in Hodgkin lymphoma: Available safety and efficacy data and ongoing evaluation
• Current role of CD30 analysis for patients with T-cell lymphoma; potential role of BV in CD30-positive disease
• Patient- and/or disease-specific factors guiding the sequence and selection of belinostat, pralatrexate and romidepsin in T-cell lymphoma
• Available data and ongoing investigation of R²-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL); current role of lenalidomide in R/R DLBCL
• CD30 testing and indications for BV in B-cell lymphomas
• Novel strategies under active investigation in hematologic cancer: chimeric antigen receptor T-cell therapy, denintuzumab mafodotin and new Bruton tyrosine kinase inhibitors, such as acalabrutinib

MODULE 2: Melanoma | 9:15 AM – 10:05 AM

• Current role of adjuvant ipilimumab in clinical practice
• Mechanism of action and administration of talimogene laherparepvec; rational integration into clinical practice
• Available data with anti-PD-1 monotherapy and combinations with anti-CTLA-4 agents for previously untreated metastatic disease; role of PD-L1 assays in clinical decision-making
• Incidence and management of autoimmune toxicities associated with immune checkpoint inhibitors
• Current role, if any, of high-dose interleukin-2 in the management of metastatic melanoma
• Indications for the use of immunotherapy as first-line treatment for BRAF-positive disease
• Clinical use of BRAF and MEK inhibitor combinations (vemurafenib/dabrafenib, trametinib/cobimetinib)
• Incidence, prevention and management of side effects and toxicities associated with available BRAF and MEK inhibitor combinations
• Management approach for patients with documented BRAF mutation-positive brain metastases
• Incidence of NRAS mutations in patients with metastatic melanoma; optimal therapeutic intervention

Break: 10:05 AM – 10:20 AM

MODULE 3: Colorectal, Gastric and Pancreatic Cancer | 10:20 AM – 11:10 AM

• Recommendation for assessment of tumor biomarkers in patients with metastatic colorectal cancer (mCRC), including RAS, BRAF, HER2, PD-1 and microsatellite instability (MSI)
• Current available data on the use of checkpoint antibodies in MSI-high colorectal cancer and current clinical indications for the use of these agents
• Anti-HER2 agents in the management of HER2-amplified mCRC
• Clinical approach to up-front therapy for patients with BRAF tumor mutations; role of FOLFOXIRI; use of BRAF inhibitors in mCRC
• Second-line treatment of RAS wild-type mCRC: Role of bevacizumab continuation, ramucirumab and aflibercept
• Toxicity considerations with the use of regorafenib and TAS-102 as later-line treatment; optimal sequencing
• Optimal management of HER2-positive gastric cancer that progresses on first-line trastuzumab/chemotherapy
• Available efficacy and safety data with checkpoint antibodies in patients with metastatic gastric or gastroesophageal junction cancer; active and proposed studies; emerging data in hepatocellular cancer
• Ongoing evaluation and current nonresearch role of FOLFIRINOX or nanoparticle albumin-bound (nab) paclitaxel/gemcitabine in the neoadjuvant and adjuvant settings
• Optimal integration of MM-398 into clinical practice: Side effects and toxicities
• Ongoing investigation of other novel agents and strategies in gastrointestinal cancer

MODULE 4: Genitourinary Cancers | 11:10 AM – 12:00 PM

• Available research data with enzalutamide and abiraterone for nonmetastatic castration-resistant prostate cancer (CRPC); potential roles in clinical practice
• Clinical factors affecting the sequence and selection of secondary hormonal therapy, immunotherapy and cytotoxic therapy for patients with metastatic CRPC (eg, prior therapies, age, performance status, symptomatology, sites of metastases)
• Emerging research information on AR-V7 as a biomarker to predict resistance to secondary hormonal therapy
• Differential mechanisms of action and available research data with other novel antiandrogens under development (eg, ARN-509, galeterone)
• Patient-specific considerations in the selection of first-line therapy for metastatic renal cell carcinoma (mRCC) (eg, age, performance status, comorbidities)
• Selection of a taxane for metastatic prostate cancer: Docetaxel versus cabazitaxel
• Currently available data supporting the use of checkpoint inhibitors in mRCC and predictors of response
• Current role of radium-223 chloride in clinical practice and rational combination strategies
• Emerging research information with cabozantinib and lenvatinib in mRCC; potential roles in clinical practice
• Current and future role of checkpoint inhibitors in metastatic bladder cancer and specific indications for the FDA-approved anti-PD-L1 agent atezolizumab

Lunch: 12:00 PM – 12:50 PM

MODULE 5: Non-Small Cell Lung Cancer (NSCLC) | 12:50 PM – 2:05 PM

• EGFR mutation variants and selection of first-line therapy
• Role of rebiopsy and serum and urine genomic assays for patients with progressive EGFR mutation-positive NSCLC; clinical implications of T790M resistance mutations
• Next-generation EGFR tyrosine kinase inhibitors: Osimertinib — available safety and efficacy data, FDA approval and indications for use in clinical practice
• Preliminary activity and ongoing evaluation of next-generation EGFR tyrosine kinase inhibitors under development
• Testing for ALK rearrangements; FISH versus next-generation sequencing; optimal first-line treatment and CNS efficacy of the 3 approved agents; FDA approval of alectinib
• Identification and clinical management of other potentially targetable mutations in NSCLC (eg, RET, BRAF, HER2)
• Available data with immune checkpoint inhibitors for patients with nonsquamous and squamous cell disease: Efficacy, toxicity and predictors of response, including PD-L1 expression; treatment for patients with preexisting autoimmune disease
• Emerging research information with anti-PD-L1 antibodies in NSCLC
• Ongoing clinical trials of anti-PD-1/PD-L1 antibodies alone or in combination with other systemic approaches
• Optimal first-line treatment of metastatic squamous cell cancer; role of necitumumab and management of associated toxicities (eg, dermatologic, hypomagnesemia)
• Second-line treatment of NSCLC and role of ramucirumab

MODULE 6: Multiple Myeloma | 2:05 PM – 2:55 PM

• Current role of autologous stem cell transplantation in the era of novel agents
• Optimal selection of induction therapy in the transplant and nontransplant settings: 2 versus 3 drugs; choice of proteasome inhibitor
• Correlation between minimal residual disease status and clinical outcomes; implications for nonresearch care and ongoing trial design
• Clinical trial evidence to guide the selection of post-transplant and nontransplant maintenance and consolidation therapy for patients with normal- and high-risk disease
• Available clinical trial data with the use of daratumumab alone or combined with a proteasome inhibitor in the R/R setting
• Current role of elotuzumab with lenalidomide in R/R disease; therapy for patients with disease progression on maintenance lenalidomide
• Ixazomib: Efficacy and tolerability; current and future use
• Current role of panobinostat with a proteasome inhibitor in R/R disease
• Emerging clinical trial evidence supporting the use of checkpoint inhibitors with immunomodulatory drugs; use of chimeric antigen receptor T-cell therapy
• New approaches to managing smoldering myeloma
• Current management of Waldenström macroglobulinemia

Break: 2:55 PM – 3:10 PM

MODULE 7: Breast Cancer | 3:10 PM – 4:00 PM

• Available and emerging data guiding the use of genomic assays to optimize decision-making regarding adjuvant chemotherapy and extended endocrine therapy
• Clinical factors affecting the selection and sequence of systemic therapy for patients with ER-positive metastatic breast cancer (mBC)
• Integration of palbociclib into clinical algorithms for patients with ER-positive mBC
• Emerging research with other CDK4/6 inhibitors (eg, abemaciclib, ribociclib)
• Optimal therapy selection for patients with triple-negative breast cancer (TNBC) in the preoperative, adjuvant and metastatic settings
• Current clinical research in TNBC, including PARP inhibitors in patients with BRCA germline mutations and anti-PD-1 and anti-PD-L1 antibodies, androgen receptor assays and novel antiandrogens for metastatic disease
• Importance of age, tumor size, nodal status and primary surgical approach in the use of neoadjuvant anti-HER2 therapy
• Ongoing and planned clinical trials incorporating novel HER2-directed therapies in the neoadjuvant and adjuvant settings
• Trials evaluating the use of dual anti-HER2 treatment: PHEREXA study of capecitabine/pertuzumab/trastuzumab; clinical decision-making in HER2-positive mBC